| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
IC50: 24.38 μM (glutathione S-transferase, GST)[1]
Glutathione S‑transferase (GST) is a phase II detoxification enzyme that catalyzes the conjugation of glutathione to electrophilic compounds. The GST-FH class of compounds, including GST-FH.4, is known to interfere with standard GST‑based assays (such as the GST pull‑down assay) by producing false positive “frequent hitter” (FH) signals due to non‑specific binding to the enzyme or the GST‑glutathione interaction pair. |
|---|---|
| ln Vitro |
In vitro, GST-FH.4 inhibits glutathione S‑transferase (GST) activity with an IC₅0 of 24.38 microM. No specific cellular activity data (e.g., cytotoxicity, cell proliferation) are reported in the search results. The compound is a chemical probe for studying GST activity and for identifying false‑positive hits in biochemical screening campaigns, but it does not exhibit pharmacological effects in cells.
|
| ln Vivo |
No in vivo activity data for GST-FH.4 are reported in the search results. As a chemical probe for GST inhibition, the compound is not intended for use in animal models and has not been evaluated for therapeutic efficacy. It serves as a research tool for in vitro biochemistry only.
|
| Enzyme Assay |
The binding of GST-FH.4 to GST is measured by standard in vitro enzyme activity assays using purified GST enzyme. The compound is incubated with GST and a chromogenic substrate (e.g., 1‑chloro‑2,4‑dinitrobenzene, CDNB) in the presence of GSH. The reaction is initiated, and product formation is monitored spectrophotometrically at 340 nm. The IC₅0 of 24.38 microM is calculated from dose‑response curves.
|
| Cell Assay |
GST-FH.4 is not evaluated in cellular assays. Its use is limited to cell‑free biochemical systems to study GST inhibition or to evaluate false‑positive interactions in GST‑based protein interaction assays. No specific cellular protocols are described. For control purposes, the compound could be added to GST pull‑down lysates to assess non‑specific binding, but no such data are reported.
|
| Animal Protocol |
GST-FH.4 is not used in animal experiments. As a research reagent for in vitro GST inhibition studies, the compound has no in vivo application. No animal protocols are described in the search results.
|
| ADME/Pharmacokinetics |
GST-FH.4 (C20H20N₆O3S, MW = 424.48, purity >98% by HPLC) is a solid powder. For storage, the powder should be kept at -20degC for up to 3 years, sealed, and protected from light. For in vitro use, stock solutions in DMSO (20 mg/mL) can be stored at -80degC for up to 1 year. For in vivo use, formulations such as 10% DMSO/40% PEG300/5% Tween‑80/45% saline are suggested, but the compound is not intended for in vivo administration.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for GST-FH.4 are reported. As a research‑grade compound, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling chemicals should be followed, including the use of gloves, lab coat, and safety goggles. No LD₅0 or formal toxicology studies are available.
|
| References | |
| Additional Infomation |
GST-FH.4 is a research‑grade GST‑FH compound used to study false‑positive “frequent hitter” interactions in GST‑based assays. The GST‑FH class of compounds was described in the literature by Brenke et al. (J Biomol Screen, 2016). The compound is for research use only and has not entered clinical trials or received regulatory approval.
|
| Molecular Formula |
C20H20N6O3S
|
|---|---|
| Molecular Weight |
424.48
|
| Exact Mass |
424.132
|
| CAS # |
1358386-87-4
|
| PubChem CID |
53137334
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(N=NN1C2=CC=CC=C2OC)C3=NSC(=N3)NC4=CC(=C(C=C4)OC)OC
|
| InChi Key |
ZNBWMKXNYIXLSW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20N6O3S/c1-12-18(23-25-26(12)14-7-5-6-8-15(14)27-2)19-22-20(30-24-19)21-13-9-10-16(28-3)17(11-13)29-4/h5-11H,1-4H3,(H,21,22,24)
|
| Chemical Name |
N-(3,4-dimethoxyphenyl)-3-[1-(2-methoxyphenyl)-5-methyltriazol-4-yl]-1,2,4-thiadiazol-5-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3558 mL | 11.7791 mL | 23.5582 mL | |
| 5 mM | 0.4712 mL | 2.3558 mL | 4.7116 mL | |
| 10 mM | 0.2356 mL | 1.1779 mL | 2.3558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
